Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | TSHR | P16473 | 5/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30584931 | 1.00 | ALDH1A1 (0.63) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL7419984 | 0.90 | ALDH1A1 (0.70) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL8139244 | 0.87 | TSHR (0.67) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL10353332 | 0.86 | TSHR (0.67) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL10352436 | 0.86 | TSHR (0.67) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL10352591 | 0.86 | TSHR (0.67) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL7260670 | 0.86 | TSHR (0.67) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL5508510 | 0.85 | ALDH1A1 (0.56) | ALDH1A1TSHRCYP2C9CYP2C19KMT2A | |
| SCHEMBL4393712 | 0.83 | ALDH1A1 (0.64) | ALDH1A1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL526330 | 0.83 | ALDH1A1 (0.73) | ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298820-A1 | 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098282-A1 | LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY | NOVASAID AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298820-A1 | 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3C2B | ALDH1A1 3530/4885TSHR 3987/4885CYP2C9 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.